Actively personalized vaccination trial for newly

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors 1,2 , For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential … Actively personalized vaccination trial for newly diagnosed glioblastoma Nature, 2019 Jan;5657738:240

Actively personalized vaccination trial for newly

Actively personalized vaccination trial for newly diagnosed glioblastoma Abstract, Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment Main, Targeting of selected neoepitopes by vaccination in …

Publisher Correction: Actively personalized vaccination

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma Nature, 2019 Feb;5667745:E13, doi: 10,1038/s41586-019-0959-z, Authors Norbert Hilf #

Actively personalized vaccination trial for newly

Actively personalized vaccination trial for newly diagnosed glioblastoma, 1, Immatics Biotechnologies GmbH, Tübingen, Germany, 11 authors 2, BioNTech AG, Mainz, Germany, 6 authors 3, Eberhard Karls Universität Tübingen, Tübingen, Germany, 5 authors 4, …

Actively personalized vaccination trial for newly

In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with

Actively personalized vaccination trial for newly

2019 Hilf et al, Nature, Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2, For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought

GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma

A Phase I Trial of Actively Personalized Peptide Vaccinations Plus Immunomodulators in Patients With Newly Diagnosed Glioblastoma Concurrent to First Line Temozolomide Maintenance Therapy: Study Start Date : October 2014: Actual Primary Completion Date : June 2018: Actual Study Completion Date : June 2018

New actively personalized therapeutic vaccine for brain

Fifteen newly diagnosed glioblastoma patients received two therapeutic vaccines in succession; the first being actively personalized vaccine 1 APVAC1 targeted at non-mutated antigens, followed by APVAC2 preferentially targeted at neo-antigens, Vaccine compositions were personalized for each patient based on analysis of the transcriptome, immunopeptidome and mutanome of the …

Actively personalized vaccination trial for newly

Actively personalized vaccination trial for newly diagnosed glioblastoma DSpace Repositorium Manakin basiert Einloggen, Publikationsdienste → Universitätsbibliographie → 4 Medizinische Fakultät → Dokumentanzeige « zurück, JavaScript is disabled for your browser, Some features of this site may not work without it, Actively personalized vaccination trial for newly diagnosed

GAPVAC-101: First-in-human trial of a highly personalized

Methods: The GAPVAC consortium realized an immunotherapy, for which personalized selection of 2 peptide-based actively personalized vaccines APVAC per patient for treatment of newly diagnosed GB was based not only on whole-exome sequencing but also on human leukocyte antigen HLA-ligandome analyses providing insight into the actual presentation of relevant epitopes in the tumor, …

Actively personalized vaccination trial for newly

Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium GAPVAC, we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma, Fifteen patients with glioblastomas positive for human leukocyte antigen …

Publisher Correction: Actively personalized vaccination

Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, Valesca Bukur, Stefan Stevanović, Cecile Gouttefangeas, Michael Platten, Ghazaleh Tabatabai, Valerie Dutoit

‪Ugur Sahin‬

Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, Nature 565 7738, 240-245 , 2019

Emerging targets for anticancer vaccination: IDH

This trial included 33 patients with newly diagnosed grade 3 and grade 4 IDH1R132H-positive astrocytomas, Patients with an oligodendroglial phenotype signified by allelic losses on chromosomes 1p and 19q and persistence of nuclear ATRX expression were excluded, All patients in the trial were treated with radiotherapy and/or chemotherapy, To avoid the inclusion of patients with …

Actively personalized vaccination trial for newly

Actively personalized vaccination trial for newly diagnosed glioblastoma, Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors 1,2, For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought